Comparison
AOD-9604 vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
221231-10-3
910463-68-2
Molecular weight
1815.09 g/mol
4113.6 g/mol
Half-life
0.4 h
165 h
Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phemodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
AOD-9604
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
3
4
of which in humans
2
3
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
1
5